IL17A and psoriasis: It was found in the skin lesions of psoriasis patients that TNF blockade with etanercept prevented TNF-mediated activation of myeloid dendritic cells, resulting in decreased IL-23 driven T-cell activation and a subsequent decrease in IL-17 levels in the skin [13].